- Home
- DFLI vs MBRX Comparison
DFLI vs MBRX Comparison
Compare DFLI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFLI | MBRX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.1M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DFLI | MBRX |
|---|---|---|
| Price | $0.46 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 321.4K | ★ 1.2M |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.41 | $0.16 |
| 52 Week High | $5.15 | $7.98 |
Technical Indicators
Market Signals| Indicator | DFLI | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 15.21 | 32.89 |
| Support Level | N/A | $0.16 |
| Resistance Level | $2.24 | $0.67 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 9.62 | 7.94 |
Price Performance
Historical ComparisonAbout DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.